Related Experiment Videos

Statin use and survival in patients with chronic heart failure--results from two observational studies with 5200

Stefan D Anker1, Andrew L Clark, Ralf Winkler

  • 1Applied Cachexia Research, Department of Cardiology, Charité Campus Virchow-Klinikum, Berlin, Germany. s.anker@imperial.ac.uk

International Journal of Cardiology
|July 19, 2006
PubMed

Insights

Statins significantly reduce mortality in chronic heart failure (CHF) patients. This benefit is observed regardless of cholesterol levels, heart failure cause, or patient condition, indicating improved survival for CHF individuals on statin therapy.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Limited evidence exists on the benefits of HMG-CoA reductase inhibitors (statins) in chronic heart failure (CHF).
  • Statins may potentially reduce mortality in CHF patients, irrespective of cholesterol levels, etiology, or clinical status.

Purpose of the Study:

  • To investigate the association between statin use and mortality in patients with chronic heart failure.
  • To determine if statin therapy impacts survival independently of key clinical factors.

Main Methods:

  • Analysis of 3132 CHF patients from the ELITE 2 study, examining baseline BMI and statin use.
  • Pooled analysis of 2068 CHF patients from 5 tertiary referral centers, assessing statin use and etiology (ischemic vs. non-ischemic).

Main Results:

  • Statin use at baseline in ELITE 2 was associated with significantly lower mortality (HR 0.61).
  • In multivariable analysis, statin therapy independently predicted lower mortality in CHF (adjusted HR 0.66).
  • In the pooled cohort, statin use was linked to reduced mortality (adjusted HR 0.58) across both ischemic and non-ischemic etiologies.

Conclusions:

  • Statin treatment is associated with reduced mortality in patients with chronic heart failure.
  • The beneficial effect of statins on mortality is independent of cholesterol levels, disease etiology, and clinical status in CHF.
Abstract

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...